Plasma-derived medicines are lifesaving biologic therapies that treat rare and chronic conditions like hemophilia and primary immunodeficiency. Their production depends on plasma donations — a precise multi-step process — and global collaboration to deliver these essential therapies to patients worldwide. Strengthening global plasma collection is key to meeting growing patient needs and maintaining a consistent plasma supply in order to manufacture lifesaving therapies.